Pfizer Acquires Amplyx Pharmaceuticals
28 Apr 2021
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
20 Apr 2021
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
StrideBio Announces Closing of $81.5M Series B Financing
16 Mar 2021
StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised $81.5 million.
Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash
4 Mar 2021
Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies.
Exscientia Completes $100 Million Series C Financing Round with BlackRock Funds
4 Mar 2021
Exscientia, a clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, today announced that funds managed by BlackRock joined the Company's Series C investment round. Including existing Series C investors, Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital, the round totalled $100 million in funding.
WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers
2 Mar 2021
WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE.
Servier to Acquire Oncology Business from Agios Pharmaceuticals
21 Dec 2020
In-line with Servier's strategy, this acquisition will enable the Group to strengthen its product portfolio and drug development pipeline in oncology.
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD
21 Dec 2020
The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China.
AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
2 Dec 2020
AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
Join Our Newsletter for Free
